Sonoma Pharmaceuticals, Inc. (SNOA)

Market Cap	3.80M
Revenue (ttm)	13.55M
Net Income (ttm)	-3.69M
Shares Out	1.34M
EPS (ttm)	-4.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	734,274
Open	3.150
Previous Close	3.160
Day's Range	2.830 - 3.170
52-Week Range	2.520 - 9.400
Beta	1.38
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About SNOA

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 25, 2007
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: SNOA
• Website: https://sonomapharma.com

Financial Performance

In 2023, Sonoma Pharmaceuticals's revenue was $12.74 million, a decrease of -4.05% compared to the previous year's $13.27 million. Losses were -$4.84 million, -6.13% less than in 2022.